JP2020523367A - Ｈ−ｐｇｄｓ阻害剤としての化学化合物 - Google Patents

Ｈ−ｐｇｄｓ阻害剤としての化学化合物 Download PDF

Info

Publication number
JP2020523367A
JP2020523367A JP2019568760A JP2019568760A JP2020523367A JP 2020523367 A JP2020523367 A JP 2020523367A JP 2019568760 A JP2019568760 A JP 2019568760A JP 2019568760 A JP2019568760 A JP 2019568760A JP 2020523367 A JP2020523367 A JP 2020523367A
Authority
JP
Japan
Prior art keywords
alkyl
naphthyridine
carboxamide
substituted
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019568760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523367A5 (https=
Inventor
デイブ、ノーマン、ディートン
バリー、ジョージ、シアラー
マーク、アンドリュー、ヤングマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2020523367A publication Critical patent/JP2020523367A/ja
Publication of JP2020523367A5 publication Critical patent/JP2020523367A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019568760A 2017-06-13 2018-06-11 Ｈ−ｐｇｄｓ阻害剤としての化学化合物 Ceased JP2020523367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762518779P 2017-06-13 2017-06-13
US62/518,779 2017-06-13
US201762522869P 2017-06-21 2017-06-21
US62/522,869 2017-06-21
PCT/IB2018/054206 WO2018229629A1 (en) 2017-06-13 2018-06-11 Chemical compounds as h-pgds inhibitors

Publications (2)

Publication Number Publication Date
JP2020523367A true JP2020523367A (ja) 2020-08-06
JP2020523367A5 JP2020523367A5 (https=) 2021-06-10

Family

ID=62948277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568760A Ceased JP2020523367A (ja) 2017-06-13 2018-06-11 Ｈ−ｐｇｄｓ阻害剤としての化学化合物

Country Status (9)

Country Link
US (1) US11149035B2 (https=)
EP (1) EP3638672A1 (https=)
JP (1) JP2020523367A (https=)
CN (1) CN110753692A (https=)
BR (1) BR112019026452A2 (https=)
CA (1) CA3066979A1 (https=)
TW (1) TW201908311A (https=)
UY (1) UY37764A (https=)
WO (1) WO2018229629A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085293A1 (en) * 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
JP2022506850A (ja) * 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CN109651241B (zh) * 2018-12-27 2021-02-09 上海毕得医药科技股份有限公司 一种4-溴-6-氯烟醛的合成方法
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
DK2142516T3 (da) 2007-03-30 2013-04-15 Sanofi Sa Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
RU2496778C2 (ru) 2009-03-09 2013-10-27 Тайхо Фармасьютикал Ко., Лтд. Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
JPWO2011043359A1 (ja) 2009-10-06 2013-03-04 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
CN107875155A (zh) 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
EP2527340B1 (en) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
US9290453B2 (en) * 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
MX363388B (es) 2012-07-27 2019-03-20 Biogen Ma Inc Agentes moduladores de autotaxina.
EA027809B1 (ru) 2012-07-27 2017-09-29 Биоген Айдек Ма Инк. Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CA2974784A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
CN108430992A (zh) * 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
US10898469B2 (en) * 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CA3085293A1 (en) * 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM COMPOUND SUMMARY, CID 91010394[ONLINE], JPN6022014006, 2015, ISSN: 0004746281 *

Also Published As

Publication number Publication date
EP3638672A1 (en) 2020-04-22
US20200123152A1 (en) 2020-04-23
US11149035B2 (en) 2021-10-19
CN110753692A (zh) 2020-02-04
UY37764A (es) 2019-01-02
CA3066979A1 (en) 2018-12-20
TW201908311A (zh) 2019-03-01
BR112019026452A2 (pt) 2020-07-14
WO2018229629A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US11149035B2 (en) Chemical compounds as H—PGDS inhibitors
US12280041B2 (en) Compounds and compositions for inducing chondrogenesis
JP6938628B2 (ja) 造血器型プロスタグランジンｄシンターゼ阻害剤としての１，３二置換シクロブタンまたはアゼチジン誘導体
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
US20210139507A1 (en) Fused pyridines which act as inhibitors of h pgds
JP2022506850A (ja) 化学化合物
HK40112804A (en) Compounds and compositions for inducing chondrogenesis
HK1231467B (en) Compounds and compositions for inducing chondrogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220408

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220826